Journal ArticleOPEN ACCESS

Continued Use of Trastuzumab Beyond Disease Progression in the National Comprehensive Cancer Network: Should We Practice Ahead of the Evidence?

  • Wong Y
  • Ottesen R
  • Hughes M
  • et al.
The Oncologist (2011) 16(5) 559-565
DOI: 10.1634/theoncologist.2010-0360
10Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The role of continued trastuzumab after progression in women with human epidermal growth factor receptor (HER)-2+ metastatic breast cancer is controversial. Controlled clinical trials that establish a benefit from continued trastuzumab have been difficult to complete.

Cite

CITATION STYLE

APA

Wong, Y.-N., Ottesen, R. A., Hughes, M. E., Niland, J. C., Theriault, R., Edge, S. B., … Weeks, J. C. (2011). Continued Use of Trastuzumab Beyond Disease Progression in the National Comprehensive Cancer Network: Should We Practice Ahead of the Evidence? The Oncologist, 16(5), 559–565. https://doi.org/10.1634/theoncologist.2010-0360

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free